As market participation expands, share shifts accelerate, demand evolves, and product innovation advances, the GLP‑1 weight loss market is entering a fundamentally new competitive phase.
Leveraging out-of-hospital retail performance and consumer behavior data, cbh (Consumer & Big Health), an Illuminera boutique, distills actionable insights at a critical inflection point where the market shifts from rapid land grab to structural reset, mass expansion, and precision operations—providing strategic guidance for brands navigating this transition.
Insight 1
Pricing Shift Reshapes Demand, Lower-Tier Markets Become the New Growth Battlefield
In early 2026, the inclusion of tirzepatide in the National Reimbursement Drug List (NRDL) triggered a broad-based price decline, lowering access barriers and expanding the core online user base from affluent tier‑1 consumers to a broader mix across all city tiers.
From Q4 2025 to Q1 2026, users from tier‑3 and below cities grew to around 45%, with lower-tier markets now accounting for nearly half of the total user base and driving the majority of incremental growth.
This signals a structural reset of the GLP‑1 consumer base: lower-tier markets are no longer peripheral but have become the key battlefield for scale expansion. Going forward, channel reach, pricing strategy, and localized understanding of lower-tier demand will directly define long-term growth potential.
Insight 2
From Ingredient Awareness to Corporate Trust, Brand Building Emerges as a New Growth Lever
In the short term, consumer awareness of GLP‑1 remains largely ingredient-driven. However, from a conversion perspective, consumers with established brand mindset demonstrate significantly higher conversion efficiency. As competition intensifies, relying solely on ingredient awareness will become increasingly challenging, making compliant brand building a critical imperative for sustained growth.
Amid tightening regulatory and communication environments, leading pharma players are shifting from product-level exposure to long-term corporate brand building. For example, Eli Lilly has strengthened corporate awareness through high-impact offline channels such as high-speed rail advertising. At the same time, online data shows that by December 2025, “Lilly” had become one of the top three most-searched brand keywords. Strong corporate branding not only drives product traffic but also reinforces overall category awareness.
Our analysis suggests that leveraging corporate brand equity to build trust in corporate value can serve as a key pathway for pharma companies to overcome communication constraints and develop long-term user assets.
Insight 3
Over 70% Drop Off After Trial, Making Retention a Critical Challenge
Across the category, GLP‑1 usage shows a strong trial-driven pattern, with over 70% of users failing to sustain long-term use - posing a structural constraint on growth. Improving patient adherence will require more mature user service models and stronger consumer education.
Further analysis shows that within the same period, the gap in repeat purchase contribution between high- and low-retention brands can reach up to 15%, highlighting a widening gap in long-term user management capabilities.
As highly consumerized therapeutic areas like GLP‑1 continue to evolve, pharma companies must go beyond policy and clinical competition to decode consumer journeys, traffic dynamics, and demand shifts through multidimensional data. Leveraging cross-industry expertise in Healthcare + FMCG, and integrating multi-source data, the cbh team has developed a differentiated analytical framework that enables more holistic strategy system.
We have recently launched an “Out-of-Hospital Retail Data Dashboard & End-to-End Solution”, supporting customized development based on specific business scenarios. By expanding data dimensions and building tailored modules aligned with strategic priorities, it covers needs from market monitoring to omni-channel user insights—empowering brands to drive sustainable, data-led growth in a rapidly evolving market.
For more relevant information, please send an email to marketing@illuminera.com.
